Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if GENB is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
19 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: neutral
Last trade: sell 42 days ago
Red flags: 0
86 filers reported a long position in GENB for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Flagship Pioneering, LLC | $1.1B | 62.7M | Unchanged |
| FMR LLC | $88.1M | 5.2M | +23.8% |
| Capital World Investors | $71.1M | 4.2M | +5.3% |
| BRAIDWELL LP | $55.4M | 3.3M | -8.6% |
| PRICE T ROWE ASSOCIATES INC /MD/ | $36.4M | 2.2M | +2.2% |
| NORGES BANK | $35.3M | 2.1M | — |
| ARCH Venture Management, LLC | $32.8M | 1.9M | Unchanged |
| HARBOURVEST PARTNERS LLC | $29.1M | 1.7M | Unchanged |
| BlackRock, Inc. | $28M | 1.7M | New |
| BAKER BROS. ADVISORS LP | $24M | 1.4M | Unchanged |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.